{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Calliditas+Therapeutics+AB",
    "query": {
      "sponsor": "Calliditas Therapeutics AB"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T10:34:25.315Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06712407",
      "title": "Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "TARPEYO®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-17",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-05T10:34:25.315Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06712407"
    },
    {
      "nct_id": "NCT03643965",
      "title": "Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Nefecon",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2018-09-05",
      "completion_date": "2023-07-10",
      "has_results": true,
      "last_update_posted_date": "2024-12-03",
      "last_synced_at": "2026-10-05T10:34:25.315Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03643965"
    },
    {
      "nct_id": "NCT02010242",
      "title": "Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus With Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "GKT137831",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 136,
      "start_date": "2013-10",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-05T10:34:25.315Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Orange, California • Coral Gables, Florida + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02010242"
    },
    {
      "nct_id": "NCT03226067",
      "title": "Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "GKT137831",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 111,
      "start_date": "2017-06-26",
      "completion_date": "2019-04-11",
      "has_results": true,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-10-05T10:34:25.315Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Ventura, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03226067"
    },
    {
      "nct_id": "NCT05014672",
      "title": "A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cholangitis",
        "Liver Stiffness"
      ],
      "interventions": [
        {
          "name": "Setanaxib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics Suisse SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2022-02-14",
      "completion_date": "2024-07-02",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-10-05T10:34:25.315Z",
      "location_count": 29,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Pasadena, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Inverness",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05014672"
    },
    {
      "nct_id": "NCT05323656",
      "title": "A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Setanaxib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Calliditas Therapeutics Suisse SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2022-04-06",
      "completion_date": "2025-08-21",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-05T10:34:25.315Z",
      "location_count": 5,
      "location_summary": "Miami Beach, Florida • City of Saint Peters, Missouri • Creve Coeur, Missouri + 2 more",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        },
        {
          "city": "Creve Coeur",
          "state": "Missouri"
        },
        {
          "city": "Florissant",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05323656"
    },
    {
      "nct_id": "NCT04541043",
      "title": "Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Nefecon 16mg daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2020-11-17",
      "completion_date": "2024-02-26",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-10-05T10:34:25.315Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541043"
    }
  ]
}